What the FDA labels say about taking them together
Enalapril and everolimus
Enalapril's FDA label of January 23, 2026 names everolimus in its drug interactions section; everolimus's label does not name enalapril itself but warns about its class (ACE inhibitors). The enalapril label: “7.6 mTOR Inhibitors Patients taking concomitant mTOR inhibitor therapy may be at increased risk for angioedema.”
Check it at the source: the enalapril FDA label on DailyMed (effective January 23, 2026, Bausch Health US LLC); the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation).
What does the enalapril label say about everolimus?
Enalapril label, drug interactionsGold Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASOTEC. mTOR (Mammalian Target of Rapamycin) Inhibitors Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS , Head and Neck Angioedema ).
Enalapril label, warningsPatients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema (see PRECAUTIONS ).
Epaned label (Azurity Pharmaceuticals, Inc., December 16, 2025), drug interactions7.6 mTOR Inhibitors Patients taking concomitant mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema [see Warnings and Precautions ( 5.2 )].
Source: FDA drug label (Epaned, NDA208686), Azurity Pharmaceuticals, Inc., effective December 16, 2025 (SPL set e6dbda02-779e-420c-893d-d0fea09432be), via openFDA
Source: FDA drug label (Vasotec), Bausch Health US LLC, effective January 23, 2026 (SPL set 39631f1f-5d19-43c1-b504-bf56d991ed97), via openFDA; the full label on DailyMed
What does the everolimus label say about enalapril?
Everolimus's label does not name enalapril itself; it warns about its class (ACE inhibitors):
Everolimus label, drug interactionsUse of Angiotensin Converting Enzyme (ACE) Inhibitors Patients taking concomitant ACE inhibitors with AFINITOR/AFINITOR DISPERZ may be at increased risk for angioedema.
Everolimus label, drug interactionsAvoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)].
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Enalapril | Everolimus | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure | Breast cancer, Seizures and epilepsy, Organ transplant rejection |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0664 per tablet 10 mg tablet | $26.32 per tablet 10 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once